ClinicalTrials.gg
CompletedNCT01681966Updated Nov 16, 2020

A Single-dose Open-Label Study to Assess the Safety and Preliminary Efficacy of PRF 110 in Open Herniorrhaphy Surgery

A Phase 2 interventional study of PRF110- oily solution (Ropivacaine) in Post Operative Pain, sponsored by PainReform LTD. Completed at 3 sites in Israel. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-16.

Sponsored by PainReform LTD · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 184 studies testing ropivacaine in Pain, Postoperative — 20 open to participants now, 22 under way, 2 of them phase 3. Ropivacaine · Pain, Postoperative.

Enrollment
164th of 184
15 · median 70
Started
2012
with 5 others
Phase 2
10 of 184
3 open now
Registered
38th of 184
by date

Among the 184 studies testing ropivacaine in Pain, Postoperative, this one is the 164th largest by enrollment, is one of 6 that started in 2012, is one of 10 in phase 2, and was the 38th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

20 of the 184 studies testing ropivacaine in Pain, Postoperative are open now, in 10 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About ropivacaine

Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies testing ropivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

LNP is new extended release (ER) oily solution formulation of ropivacaine that is intended for local infiltration into surgical wounds. The purpose of this study is to determine the ease of usage and administration of LNP in the surgical setting, to follow the Pharmacokinetic (PK) profile of LNP over 72 hours and evaluate the duration of analgesia witnessed in the surgical setting.

Read the detailed description

LNP is new extended release (ER) oily solution formulation of ropivacaine that is intended for local infiltration into surgical wounds. The formulation is designed to slowly release the ropivacaine over 36-72 hours. By providing local analgesia over a long time span, the need for systemic analgesics is expected to be reduced and hospital stays may be shortened. The purpose of this study is to determine the ease of usage and administration of LNP in the surgical setting, to follow the PK profile of LNP over 72 hours and evaluate the duration of analgesia witnessed in the surgical setting.

03

Conditions studied

  • Post Operative Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male subjects between 18-70 years of age who are scheduled to undergo open one sided herniorrhaphy surgery;
  • Subjects have a of less than 30 kg/m2;
  • Subjects are in good physical health (other than the need for the surgical procedure) as judged by physical and laboratory examinations and have a negative urine based screen for drugs of abuse;
  • Subjects must agree to refrain from ingesting any analgesic medication for at least 2 days (or 5 half-lives of the analgesic drug) prior to surgery; refrain from alcohol and excessive caffeine intake on the day of surgery and during 72 hours after surgery;
  • Subject must be capable of reading, comprehending, and signing the form;

Exclusion criteria

Exclusion Criteria:

  • Subjects with a history of melena or any significant hepatic, renal, endocrine, cardiac, neurological, psychiatric, gastrointestinal, pulmonary, hematologic, or metabolic disorders;
  • Subjects with a history of any type of cancer within 5 years of surgery;
  • Subjects with any history of alcohol or substance abuse;
  • Subjects that have a history of uncontrolled hypertension;
  • Subjects with a known to any local anesthetic drug;
  • Subjects with a concentration of less than 10.0 g/dL;
  • Subjects with any abnormal lab result (as judged by the Principal Investigator);
  • Subjects with atrial fibrillation/flutter, an inserted pacemaker, or complete left bundle branch block (LBBB) on ; or myocardial infarction within 6 months prior to surgery;
  • Subjects with a clinically significant abnormal ECG at screening;
  • Subjects with any condition or history judged by the Investigator to place the subject at increased risk;
  • Subjects judged by the Investigator to be unable or unwilling to comply with the requirements of the protocol;
  • Subjects who have used an drug within 30 days prior to entering the study;
  • Subjects who have donated blood within 3 months prior to the start of the study;
  • Subjects who are members of the study site staff directly involved with the study or a relative of the Sponsor or other personnel involved with the study;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Application of PRF110- oily solution

    Post operative application of new extended release PRF110- oily solution (Ropivacaine)

    Drug: PRF110- oily solution (Ropivacaine)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events (safety and tolerability).

    All adverse events (AE) reported by the subjects will be recorded throughout the trial period

    Time frame: 72 hours

Secondary outcomes

  1. Post-operative Pain intensity

    Pain on a scale of 0-10 assessed at 0,1,2,4,8,12,24,36,48,60,72hrs post operation will be used to evaluate pain intensity

    Time frame: 72 hours

Other outcomes

  1. Use of rescue medication

    Overall use of rescue medication post operation

    Time frame: 72 hours

  2. Maximum plasma concentration (Cmax)

    Samples will be collected at designated times up to 72hrs post drug application

    Time frame: 72 hrs

07

Study locations

3 sites
  • Western Galil Medical Center
    Nahariya, 2210001, Israel
  • Assaf Harofeh Medical Center
    Rishon LeZion, Israel
  • Sourasky Medical Center
    Tel Aviv, Israel
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2012
First posted
Sep 10, 2012
Start
Sep 2012
Primary completionActual
May 4, 2016
CompletionActual
May 4, 2016
Last update
Nov 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01681966
Lead sponsor
PainReform LTD
Responsible party
Sponsor
First posted
Sep 10, 2012
Start date
Sep 2012
Primary completion
May 4, 2016
Completion
May 4, 2016
Last update
Nov 16, 2020

Study contacts

Moaad Farraj, Dr.
principal investigator · Galilee Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion